Joseph Frank Oldakowski - 16 Jun 2026 Form 4 Insider Report for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

Reporting relationship: VP OF FINANCE AND CONTROLLER
Issuer ticker: CLOV
Reported as of: 16 Jun 2026
Net transaction value: -$58,816
SEC form: 4
Accepted by SEC: 17 Jun 2026, 08:13:30 UTC
Prior SEC filing: 09 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Peter J. Rivas as attorney-in-fact for Joseph Frank Oldakowski

Key filing fact

Joseph Frank Oldakowski filed Form 4 for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) on 17 Jun 2026.

Key facts

This page summarizes Joseph Frank Oldakowski's Form 4 filing for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Jun 2026, 08:13.

Change

Previous filing in this sequence was filed on 09 Apr 2026.
Current net transaction value: -$58,816.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002128814 Primary reporting owner

OLDAKOWSKI JOSEPH FRANK

Relationship: VP OF FINANCE AND CONTROLLER
Address: C/O CLOVER HEALTH INVESTMENTS, CORP., WILMINGTON
Signature: /s/ Peter J. Rivas as attorney-in-fact for Joseph Frank Oldakowski
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLOV transaction

Class A Common Stock

Sale

Transaction value: $58,816
Shares: -12,102
Change %: -3.9%
Price: $4.86
Shares after: 299,067
Date: 16 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 25% of restricted stock units ("RSUs") originally granted to the Reporting Person on June 16, 2025. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on June 16, 2029, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.